The top executives of most of America's biggest corporations are adept at dodging taxes, overpaying themselves, and buying back shares that they are invested in themselves rather than building rainy day funds. The Federal government and Federal Reserve are the backstops in the mythical land of free markets while the genesis of commercial pharmaceutical and tech innovations are often in public laboratories or institutions.
Fortune magazine noted last August that more than half of all share buybacks were funded by debt.
According to a January 2020 article in the Harvard Business Review, "in 2018, only 43% of companies in the S&P 500 Index recorded any R&D expenses, with just 38 companies accounting for 75% of the R&D spending of all 500 companies....The 465 companies in the S&P 500 Index in January 2019 that were publicly listed in 2009-2018 spent $4.3tn on buybacks, equal to 52% of net income, and another $3.3tn on dividends — an additional 39% of net income. In 2018 alone, even with after-tax profits at record levels because of the Republican tax cuts, buybacks by S&P 500 companies reached an astounding 68% of net income, with dividends absorbing another 41%."